Clinical evaluation of therapeutic efficacy of Teriparatide in osteoporotic patients with vertebral degeneration

IF 1.5 Q3 ORTHOPEDICS

Journal of orthopaedics Pub Date : 2024-12-30 DOI:10.1016/j.jor.2024.12.045

Masoud Mirkazemi , Behdad Nadimi , Parnin Soltani , Golshan Eslami , Yasaman Parvisi , Maryam Garousi , Azra Izanloo

{"title":"Clinical evaluation of therapeutic efficacy of Teriparatide in osteoporotic patients with vertebral degeneration","authors":"Masoud Mirkazemi , Behdad Nadimi , Parnin Soltani , Golshan Eslami , Yasaman Parvisi , Maryam Garousi , Azra Izanloo","doi":"10.1016/j.jor.2024.12.045","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/objective</h3><div>Osteoporosis is a common age-associated bone disease characterized by the decreased bone density and compromised bone strength. Osteoporotic patients are always at a risk of severe fractures and they experience chronic lumbar pain, highlighting the need for an effective treatment while having lowest side effects. This clinical evaluation of three years from 2018 to 2021 at a single clinic in western Tehran, Iran was aimed to evaluate the therapeutic effects of a biosimilar recombinant teriparatide traded as ‘Cinnopar®’ to alleviate the back pain and manage thoracolumbar osteoporosis.</div></div><div><h3>Methods</h3><div>In this study, a total of 180 osteoporotic patients diagnosed with lower back pain, were enrolled and later on 14 patients were excluded from the study due to lack of cooperation or follow-up. Patients were randomly assigned into two groups, one those who are willingly will be receiving CinnoPar® and second group who will be receiving bisphosphonates at an optimal monthly dose. Data was collected through reviews of medical records and comprehensive regular follow-up was performed via phone interviews to evaluate bone density and pain levels during specific intervals of time. Oswestry Disability Index (ODI) was developed and Short Form Health Survey (SF-36) was performed to analyses the results from two under treatment groups.</div></div><div><h3>Results and conclusion</h3><div>Significant improvement in pain and functional ability was observed in the patients who received CinnoPar® after two years as compared to the bisphosphonate group (P < 0.05). It was also reported that patients who received CinnoPar® showed improvements in social functioning and pain reduction over the same period of time (P < 0.05). CinnoPar® showed promising results and fall under a minimally invasive treatment category for reducing the lower back pain and managing osteoporosis in lumbar and thoracic vertebrae while having few side effects.</div></div>","PeriodicalId":16633,"journal":{"name":"Journal of orthopaedics","volume":"66 ","pages":"Pages 104-109"},"PeriodicalIF":1.5000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of orthopaedics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0972978X24004732","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objective

Osteoporosis is a common age-associated bone disease characterized by the decreased bone density and compromised bone strength. Osteoporotic patients are always at a risk of severe fractures and they experience chronic lumbar pain, highlighting the need for an effective treatment while having lowest side effects. This clinical evaluation of three years from 2018 to 2021 at a single clinic in western Tehran, Iran was aimed to evaluate the therapeutic effects of a biosimilar recombinant teriparatide traded as ‘Cinnopar®’ to alleviate the back pain and manage thoracolumbar osteoporosis.

Methods

In this study, a total of 180 osteoporotic patients diagnosed with lower back pain, were enrolled and later on 14 patients were excluded from the study due to lack of cooperation or follow-up. Patients were randomly assigned into two groups, one those who are willingly will be receiving CinnoPar® and second group who will be receiving bisphosphonates at an optimal monthly dose. Data was collected through reviews of medical records and comprehensive regular follow-up was performed via phone interviews to evaluate bone density and pain levels during specific intervals of time. Oswestry Disability Index (ODI) was developed and Short Form Health Survey (SF-36) was performed to analyses the results from two under treatment groups.

Results and conclusion

Significant improvement in pain and functional ability was observed in the patients who received CinnoPar® after two years as compared to the bisphosphonate group (P < 0.05). It was also reported that patients who received CinnoPar® showed improvements in social functioning and pain reduction over the same period of time (P < 0.05). CinnoPar® showed promising results and fall under a minimally invasive treatment category for reducing the lower back pain and managing osteoporosis in lumbar and thoracic vertebrae while having few side effects.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of orthopaedics ORTHOPEDICS-

CiteScore

3.50

自引率

6.70%

发文量

202

审稿时长

56 days

期刊介绍： Journal of Orthopaedics aims to be a leading journal in orthopaedics and contribute towards the improvement of quality of orthopedic health care. The journal publishes original research work and review articles related to different aspects of orthopaedics including Arthroplasty, Arthroscopy, Sports Medicine, Trauma, Spine and Spinal deformities, Pediatric orthopaedics, limb reconstruction procedures, hand surgery, and orthopaedic oncology. It also publishes articles on continuing education, health-related information, case reports and letters to the editor. It is requested to note that the journal has an international readership and all submissions should be aimed at specifying something about the setting in which the work was conducted. Authors must also provide any specific reasons for the research and also provide an elaborate description of the results.